Go to article: Home | What Rishi Sunak can do for the UK pharma industry Go to article: In this issueGo to article: ContentsGo to article: CSafeGo to article: TripletreeGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: BEA TechnologiesGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CommentGo to article: GSK speeds up the race to market first RSV vaccine for older adultsGo to article: Biden’s directive on foreign biotech investments impacts manufacturersGo to article: Novo Nordisk targets FDA approval for once-weekly insulin after Phase III dataGo to article: ‘Twindemic’ risks warrant immediate steps in Europe and the US Go to article: A game of two halves for Roche’s recently approved wet AMD assetsGo to article: Dr. Paul LohmannGo to article: NiproGo to article: In DepthGo to article: What Rishi Sunak can do for the UK pharma industryGo to article: Inside the European mass shift to data-driven health solutionsGo to article: Chronic drug shortages signal difficult outlook for cardiovascular careGo to article: Can gene therapies for haemophilia defend their high price tags?Go to article: Trial termination analysis unveils a silver lining for patient recruitmentGo to article: New dawn for the EU's joint procurement crisis responseGo to article: SkyepharmaGo to article: Bio Image Systems Inc.Go to article: In DataGo to article: The pharma industry found it easier to fill AI vacancies in Q3 2022 Go to article: Internet of things hiring levels in the pharma dropped in October 2022Go to article: Artificial intelligence hiring levels in the pharma dropped in October 2022Go to article: BaxterGo to article: EventsGo to article: Next issue